Company announcement no. 01-2026
Copenhagen, 2026.03.05
Monsenso’s annual report for 2025 was approved by the Board of Directors today.
Performance highlights
Business development
Thomas Lethenborg, CEO says:
“Digital health is definitely high on the agenda across both public and private providers, research institutions and pharmaceuticals. The realisation that the combination of continuous patient-reported outcomes monitoring for deeper insights and data-driven, blended care is key to efficient future healthcare delivery is growing.”
Outlook for 2026
For 2026, we expect revenue of around DKK 11m, corresponding to 24% growth, with an EBIT of DKK -4m. The expectations are associated with significant uncertainties, including going concern, which are described in notes 2 and 3 to the financial statements.
Key figures |
|
|
('000 DKK) | 2025 | 2024 |
Revenue | 8,907 | 11,165 |
EBITDA | (2,961) | (2,053) |
EBIT | (7,582) | (6,481) |
Profit (loss) for the year | (7,217) | (6,001) |
|
|
|
Cash and cash equivalents | 54 | 1,861 |
Total assets, end of year | 13,050 | 18,490 |
Equity, end of year | 6,976 | 14,164 |
|
|
|
Net profit per share (DKK) | (0.11) | (0.12) |
End-of-year, number of employees (FTE) | 10 | 13 |
CEO Thomas Lethenborg and CFO Robert Højer have recorded a video that comments on the annual report. The link is here: https://www.monsenso.com/investors/.
Disclaimer
This report contains forward-looking statements which are based on the current expectations of the management. All statements regarding the future are subject to inherent risks and uncertainties, and many factors can lead to actual results and developments deviating substantially from what has been expressed or implied in such statements.
Any inquiries regarding this notice should be directed to:
Monsenso
CEO
Thomas Lethenborg
Tel +45 21 29 88 27
E-mail: lethenborg@monsenso.com
Chairman of the board
Peter Mørch Eriksen
E-mail: Petermorcheriksen@outlook.com
Certified Adviser
HC Andersen Capital
Bredgade 23,
1260 København K
Monsenso is an innovative technology company offering a digital health solution used for decentralised trials, remote patient monitoring and treatment support. Our mission is to contribute to improved health for more people at lower costs by supporting treatment digitally and leveraging patient-reported outcomes data. Our solution helps optimise the treatment and gives a detailed overview of an individual’s health through the collection of outcome, adherence and behavioral data. It connects individuals, carers and health care providers to enable personalised treatment, remote care and early intervention. We collaborate with health and social care, pharmaceuticals and leading researcher worldwide in our endeavors to deliver solutions that fit into the lives of patients and health care professionals. To learn more visit www.monsenso.com